Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib

BACKGROUND: Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), is highly effective in the treatment of patients with chronic myeloid leukemia (CML), despite being more vasculotoxic than older TKIs such as imatinib. Herein, we present a case of nilotinib-associated vasospastic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruta, Shunsuke, Usami, Kyohei, Tajiri, Kazuko, Otani, Masafumi, Hiraya, Daigo, Watabe, Hiroaki, Hoshi, Tomoya, Sato, Akira, Ieda, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393793/
https://www.ncbi.nlm.nih.gov/pubmed/34452646
http://dx.doi.org/10.1186/s40959-021-00119-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393793/
https://www.ncbi.nlm.nih.gov/pubmed/34452646
http://dx.doi.org/10.1186/s40959-021-00119-6

Ejemplares similares